LOX and cholangiocarcinoma: Fibroblast-derived LOX—abundant in iCCA stroma—increases tumor OXPHOS and stemness, linking matrix cross-linking to metabolic hard-wiring and aggressive behavior; pharmacologic LOX inhibition remodels the fibro-inflammatory stroma and sensitizes CCA to therapy in preclinical studies (28).